Generic Name and Formulations:
Vorapaxar 2.08mg (equivalent to 2.5mg of vorapaxar sulfate); tabs.
Indications for ZONTIVITY:
To reduce thrombotic cardiovascular events in patients with a history of myocardial infarction or with peripheral arterial disease.
2.08mg once daily. Use with aspirin and/or clopidogrel according to their indications or standard of care.
History of stroke, transient ischemic attack (TIA), or intracranial hemorrhage (ICH). Active pathological bleeding (eg, peptic ulcer, ICH).
Discontinue if stroke, TIA, or ICH occurs. Increased risk of bleeding (may be fatal). Consider underlying risk of bleeding before initiating (eg, older age, low body wt., reduced renal or hepatic function, history of bleeding disorders, concomitant certain medications). Hypotensive and has recently undergone coronary angiography, PCI, CABG or other surgeries: suspect bleeding and monitor. Severe hepatic impairment: not recommended. Elderly. Pregnancy (Cat. B). Nursing mothers: not recommended.
Avoid concomitant strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, posaconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, boceprevir, telaprevir, telithromycin, conivaptan). Avoid concomitant strong CYP3A4 inducers (eg, rifampin, carbamazepine, St. John’s wort, phenytoin). Avoid concomitant warfarin or other anticoagulants. Increased risk of bleeding with concomitant fibrinolytics, chronic NSAIDs, SSRIs, SNRIs.
Protease-activated receptor-1 (PAR-1) antagonist.
Bleeding (may be fatal), anemia, depression, rashes, eruptions, exanthemas, iron deficiency, retinopathy or retinal disorder, diplopia/oculomotor disturbances.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- A Witness to Letting Go: Nursing Care at the End of Life
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Intervention Improves Breast Cancer Survivors' Memory Contentment
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Patients With Head and Neck Cancer Have Greater Chance of Being Prescribed Opioids
- Medical Terms in Patient Education: Using the Confusing to Explain the Complicated
- Bedside Assessment Tool Improves Worst Pain in Patients With Cancer
- Androgen-Deprivation Therapy for Prostate Cancer May Cause Nocturia, Sleep Disturbance
- USPSTF Rates Ovarian Cancer Screening a D for Asymptomatic, Low-Risk Women
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|